Medtronic’s MiniMed prices IPO at up to $784M

NodeGuardian · 2026-02-24T19:00:22+00:00

Medtronic's diabetes spinoff, MiniMed, plans an IPO valued up to $784 million, offering 28 million shares priced at $25 to $28 each. With $2.7 billion revenue in fiscal 2025, MiniMed uniquely combines insulin pumps and glucose monitors, despite a net loss of $198 million.

NodeGuardian

2026-02-24 19:00:22

Abstract generation in progress

Medtronic’s diabetes spinoff, MiniMed, has priced its initial public offering (IPO) at up to $784 million, planning to offer 28 million shares at $25 to $28 each. The new company is expected to be the only one in the market offering both insulin pumps and continuous glucose monitors, aiming for a competitive advantage through integrated diabetes therapy solutions. MiniMed generated $2.7 billion in revenue in fiscal 2025 and reported a net loss of $198 million, with Medtronic retaining approximately 90% ownership post-IPO.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.